James Karis
Chief Executive Officer at Mapi Group
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Alex Tabatabai | M | 42 | 8 years | |
Hans-Peter Hasler | M | 68 | 6 years | |
Paul Spoors | M | - | 5 years | |
Peter Llewellyn-Davies | M | 66 | 8 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Philip C. Ranker | M | 64 | 7 years | |
Peter García | M | 62 |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | 2 years |
Joseph W. Ramelli | M | 55 | 6 years | |
Joanne Elizabeth Estell | F | 53 | - | |
Bruce R. York | M | 69 |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | 6 years |
Angela Hildreth | F | - | 6 years | |
Laurence P. Birch | M | 64 | 8 years | |
Richard Jones | M | 58 | 7 years | |
Gregory Sessler | M | 71 |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | 4 years |
Carl Sterritt | M | 55 | 12 years | |
Tim Watts | M | 66 | 3 years | |
James Rob Ward | M | 63 | 5 years | |
Michael Taylor | M | 69 | 2 years | |
James Rothman | M | 74 |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | 2 years |
Richard Theodore Ho | M | 61 |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA. | 6 years |
Karl Keegan | M | 57 | 1 years | |
J. Michael French | M | 63 |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | 8 years |
June D. Ameen | F | 67 |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | 1 years |
Alan S. Blazei | M | 68 |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA. | - |
Rolf K. Hoffmann | M | 64 | 3 years | |
Chiang J. Li | M | 59 | 1 years | |
Daniel L. Peters | M | 72 |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | 2 years |
Stefan Loren | M | 60 | 5 years | |
Andrew Thomas Pitler | M | - | 1 years | |
Jerome H. Kaiser | M | 67 | 17 years | |
Barry A. Polisky | M | 78 |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | 2 years |
Bruce R. Thaw | M | 71 |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | 26 years |
Jay Tenenbaum | M | - |
CollabRx, Inc. /Old/
CollabRx, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward. | - |
Jack Jacobs | M | 77 | 6 years | |
Raphael Lehrer | M | - |
CollabRx, Inc. /Old/
CollabRx, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward. | - |
Smruti J. Vidwans | M | - |
CollabRx, Inc. /Old/
CollabRx, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward. | - |
Michael Houston | M | 61 | 8 years | |
Mike Koo | M | - |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA. | 3 years |
Niki Kutac | F | - | - | |
Alison D. Silva | F | 46 | 3 years | |
Didier Scherrer | M | - |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA. | 5 years |
Suzanne Wood | F | - | - | |
Paul Steckler | M | - | - | |
Mark Sampson | M | - | 5 years | |
Nicholas A. Loiacono | M | 71 | 3 years | |
Catherine Ley | M | - |
CollabRx, Inc. /Old/
CollabRx, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward. | - |
Andrew Heath | M | 76 | 2 years | |
Aytek Çelik | F | - |
CollabRx, Inc. /Old/
CollabRx, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward. | - |
R. Fletcher | M | 78 | 1 years | |
Jon Saxe | M | 88 |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA. | - |
Steven Engle | M | 69 |
The Bay Area Bioscience Association
| - |
Peter D. Parker | M | 73 | 2 years | |
Robert Rodin | M | 70 |
CollabRx, Inc. /Old/
CollabRx, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward. | - |
Gregory Schiffman | M | 67 |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA. | - |
Alan Dunton | M | 70 | 6 years | |
Per A. Peterson | M | 79 |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA. | - |
Jeffrey E. Devers | M | 69 |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA. | 5 years |
Jonathan MacQuitty | M | 71 |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA. | 7 years |
Jeff Shrager | M | - |
CollabRx, Inc. /Old/
CollabRx, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward. | - |
Kai Milderberger | M | - |
CollabRx, Inc. /Old/
CollabRx, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward. | - |
Ed D. Bell | M | - |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | - |
Simon Geoffrey Best | M | 67 |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA. | - |
Tim Biro | M | 70 | 24 years | |
John T. Rigsbee | M | 61 |
Entelos, Inc.
Entelos, Inc. Information Technology ServicesTechnology Services Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA. | - |
Craig Wigginton | M | - | - | |
Henry R. Costantino | M | - |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | 7 years |
Matthew D. Haines | M | - |
MDRNA, Inc.
MDRNA, Inc. Miscellaneous Commercial ServicesCommercial Services MDRNA, Inc. engages in development and commercialization of innovative products based on proprietary molecular biology-based intranasal drug delivery technology. The company creates or utilizes novel formulation components or excipients that can transiently manipulate or open 'tight junctions' between cells in various tissues and thereby allow therapeutic drugs to reach the blood stream. The company is located in Hauppauge, NY. | - |
Jonathan Jacoby | M | - |
CollabRx, Inc. /Old/
CollabRx, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services CollabRx uses information technology to inform personalized cancer treatment planning by combining the world's knowledge on cutting-edge therapies with specific insights from the nation's top cancer experts starting with the area of greatest need advanced cancers in patients who have effectively exhausted the standard of care. For physicians, Collabrx provides sophisticated, yet intuitive decision support tools to help them rapidly and accurately determine which medical tests, therapies, and clinical trials should be considered in order to deliver the best possible care to their patients. For patients, CollabRx provides actionable and highly-credible information that can be shared with their oncologist in a form that supports collaborative decision making in determining a cancer treatment plan that is customized for them. For researchers, CollabRx provides a framework to categorize the molecular subtypes of cancer based on the genetic profile of the tumor, and more importantly link specific subtypes to relevant treatments and ultimately patient clinical outcomes to drive the science and medicine forward. | - |
Walt Townsend | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 54 | 79.41% |
United Kingdom | 14 | 20.59% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Karis
- Personal Network